Novo Nordisk A/S Class B Total Current Liabilities

Novo Nordisk A/S Class B (NONOF) currently reports a total current liabilities of $230B as of March 2026. That compares with $240B in the prior-year period — down 4.6% year over year. Use the charts on this page to explore Novo Nordisk A/S Class B's total current liabilities history and peer comparisons.

Novo Nordisk A/S Class B's total current liabilities decreased from $240B to $230B — a 4.6% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Novo Nordisk A/S Class B reported $230B in total current liabilities as of March 2026. That compares with $240B in the prior-year period — down 4.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $230B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Novo Nordisk A/S Class B, and consider following NONOF for alerts when major investors trade the stock.

Novo Nordisk A/S Class B is classified in the Healthcare sector. On total current liabilities, it currently shows $230B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NONOF with unrelated industries.